JP2020503362A5 - - Google Patents

Download PDF

Info

Publication number
JP2020503362A5
JP2020503362A5 JP2019536919A JP2019536919A JP2020503362A5 JP 2020503362 A5 JP2020503362 A5 JP 2020503362A5 JP 2019536919 A JP2019536919 A JP 2019536919A JP 2019536919 A JP2019536919 A JP 2019536919A JP 2020503362 A5 JP2020503362 A5 JP 2020503362A5
Authority
JP
Japan
Prior art keywords
antibody
seq
cdr
fibrosis
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019536919A
Other languages
English (en)
Japanese (ja)
Other versions
JP7157744B2 (ja
JP2020503362A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/012601 external-priority patent/WO2018129329A1/en
Publication of JP2020503362A publication Critical patent/JP2020503362A/ja
Publication of JP2020503362A5 publication Critical patent/JP2020503362A5/ja
Priority to JP2022162088A priority Critical patent/JP2022188226A/ja
Application granted granted Critical
Publication of JP7157744B2 publication Critical patent/JP7157744B2/ja
Priority to JP2024172672A priority patent/JP2025000891A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019536919A 2017-01-06 2018-01-05 アイソフォーム特異的な、コンテクスト寛容TGFβ1阻害剤およびその使用 Active JP7157744B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022162088A JP2022188226A (ja) 2017-01-06 2022-10-07 アイソフォーム特異的な、コンテクスト寛容TGFβ1阻害剤およびその使用
JP2024172672A JP2025000891A (ja) 2017-01-06 2024-10-01 アイソフォーム特異的な、コンテクスト寛容TGFβ1阻害剤およびその使用

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US201762443615P 2017-01-06 2017-01-06
US62/443,615 2017-01-06
US201762452866P 2017-01-31 2017-01-31
US62/452,866 2017-01-31
US201762514417P 2017-06-02 2017-06-02
US62/514,417 2017-06-02
US201762529616P 2017-07-07 2017-07-07
US62/529,616 2017-07-07
US201762549767P 2017-08-24 2017-08-24
US62/549,767 2017-08-24
US201762558311P 2017-09-13 2017-09-13
US62/558,311 2017-09-13
US201762585227P 2017-11-13 2017-11-13
US62/585,227 2017-11-13
US201762587964P 2017-11-17 2017-11-17
US62/587,964 2017-11-17
US201762588626P 2017-11-20 2017-11-20
US62/588,626 2017-11-20
PCT/US2018/012601 WO2018129329A1 (en) 2017-01-06 2018-01-05 ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFβ1 INHIBITORS AND USE THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022162088A Division JP2022188226A (ja) 2017-01-06 2022-10-07 アイソフォーム特異的な、コンテクスト寛容TGFβ1阻害剤およびその使用

Publications (3)

Publication Number Publication Date
JP2020503362A JP2020503362A (ja) 2020-01-30
JP2020503362A5 true JP2020503362A5 (https=) 2021-02-12
JP7157744B2 JP7157744B2 (ja) 2022-10-20

Family

ID=61198888

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019536919A Active JP7157744B2 (ja) 2017-01-06 2018-01-05 アイソフォーム特異的な、コンテクスト寛容TGFβ1阻害剤およびその使用
JP2022162088A Pending JP2022188226A (ja) 2017-01-06 2022-10-07 アイソフォーム特異的な、コンテクスト寛容TGFβ1阻害剤およびその使用
JP2024172672A Pending JP2025000891A (ja) 2017-01-06 2024-10-01 アイソフォーム特異的な、コンテクスト寛容TGFβ1阻害剤およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022162088A Pending JP2022188226A (ja) 2017-01-06 2022-10-07 アイソフォーム特異的な、コンテクスト寛容TGFβ1阻害剤およびその使用
JP2024172672A Pending JP2025000891A (ja) 2017-01-06 2024-10-01 アイソフォーム特異的な、コンテクスト寛容TGFβ1阻害剤およびその使用

Country Status (17)

Country Link
US (3) US20180207267A1 (https=)
EP (1) EP3551658A1 (https=)
JP (3) JP7157744B2 (https=)
KR (2) KR20190098255A (https=)
CN (2) CN117398457A (https=)
AU (2) AU2018205231A1 (https=)
BR (1) BR112019013908A2 (https=)
CA (1) CA3049005A1 (https=)
CL (1) CL2019001874A1 (https=)
CO (1) CO2019007298A2 (https=)
CR (1) CR20190350A (https=)
DO (1) DOP2019000180A (https=)
IL (2) IL267790A (https=)
MX (1) MX2019008197A (https=)
PE (1) PE20191661A1 (https=)
PH (1) PH12019501575A1 (https=)
WO (1) WO2018129329A1 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3055555A1 (en) 2016-03-11 2017-09-14 Scholar Rock, Inc. Tgf.beta.1-binding immunoglobulins and use thereof
BR112019013908A2 (pt) * 2017-01-06 2020-02-04 Scholar Rock, Inc. inibidores de tgfss1 isoforma-específicos, contexto-permissivos, e seus usos
MA49690A (fr) * 2017-07-28 2021-05-19 Scholar Rock Inc Inhibiteurs spécifiques du complexe ltbp de tgf-bêta 1 et leurs utilisations
EP3694552A1 (en) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
SI3677278T1 (sl) 2018-07-11 2022-01-31 Scholar Rock, Inc. Izoformno selektivni zaviralci TGFBETA1 in uporaba le-teh
US20210340238A1 (en) 2018-07-11 2021-11-04 Scholar Rock, Inc. TGFß1 INHIBITORS AND USE THEREOF
MA53125A (fr) 2018-07-11 2021-05-19 Scholar Rock Inc Inhibiteurs de tgf?1 sélectifs selon l'isoforme à affinité élevée
CN113164780A (zh) 2018-10-10 2021-07-23 泰洛斯治疗公司 抗lap抗体变体及其用途
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN113677711B (zh) 2019-01-30 2025-05-30 供石公司 TGFβ的LTBP复合特异性抑制剂及其用途
SG11202110338XA (en) 2019-03-27 2021-10-28 Singapore Health Serv Pte Ltd Biomarker with therapeutic implications for peritoneal carcinomatosis
US20220160751A1 (en) * 2019-04-02 2022-05-26 Yale University Methods of treatment of diseases and disorders associated with increased tet level, increased h19 level, increased level of tgf signaling, or any combination thereof
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
CN114729370B (zh) 2019-08-28 2025-03-21 中外制药株式会社 跨物种抗潜伏TGF-β1抗体和使用方法
EP4058144A1 (en) 2019-11-15 2022-09-21 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof
CA3166328A1 (en) * 2020-01-11 2021-07-15 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
TW202135862A (zh) * 2020-01-11 2021-10-01 美商供石公司 TGFβ抑制劑及其用途
HRP20240182T1 (hr) 2020-03-26 2024-04-26 Vanderbilt University Ljudska monoklonska protutijela za teški akutni respiratorni sindrom koronavirusa 2 (sars-cov-2)
US20230122364A1 (en) * 2020-03-27 2023-04-20 Vanderbilt University HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
MX2022013499A (es) 2020-04-27 2023-01-16 Twist Bioscience Corp Bibliotecas de ácidos nucleicos variantes para coronavirus.
EP4161936A1 (en) 2020-06-03 2023-04-12 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
WO2022116877A1 (en) * 2020-12-02 2022-06-09 Shanghai Henlius Biotech, Inc. ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE
CN114957476A (zh) * 2021-02-23 2022-08-30 复旦大学 一种半胱氨酸工程化的结合人5t4的全人源纳米抗体
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
WO2022240879A1 (en) 2021-05-11 2022-11-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
KR20240007233A (ko) 2021-05-13 2024-01-16 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
EP4348260A2 (en) 2021-06-03 2024-04-10 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
EP4370148A1 (en) 2021-07-14 2024-05-22 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf beta1 and uses thereof
IL310164A (en) * 2021-08-11 2024-03-01 Hcw Biologics Inc Multi-chain chimeric polypeptides and use thereof in the treatment of liver diseases
WO2023107938A1 (en) 2021-12-08 2023-06-15 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
KR20240123836A (ko) 2021-12-22 2024-08-14 길리애드 사이언시즈, 인코포레이티드 이카로스 아연 핑거 패밀리 분해제 및 이의 용도
US12122764B2 (en) 2021-12-22 2024-10-22 Gilead Sciences, Inc. IKAROS zinc finger family degraders and uses thereof
WO2023178181A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
EP4501928A4 (en) 2022-03-22 2026-04-01 Autotelic Bio Inc Thiazole-derived compound and its uses
AU2023409398A1 (en) 2022-12-22 2025-06-05 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024187051A1 (en) 2023-03-07 2024-09-12 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
CR20250446A (es) 2023-04-21 2025-12-02 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
CN117721079B (zh) * 2024-01-26 2025-03-11 广东壹加再生医学研究院有限公司 一种促进nk细胞抗肿瘤活性的培养基及培养方法
WO2025240343A1 (en) 2024-05-13 2025-11-20 Scholar Rock, Inc. Tgf-beta inhibitors for treating cancer
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
NZ331688A (en) 1996-03-28 2000-02-28 Univ Johns Hopkins Soluble divalent and multivalent heterodimeric analogs of proteins
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
KR100919593B1 (ko) 2000-06-29 2009-09-29 아보트 러보러터리즈 이중 특이성 항체 및 이의 제조 방법 및 이를 포함하는 조성물
GB0230202D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Ligand
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
TR201901929T4 (tr) 2005-02-08 2019-03-21 Genzyme Corp TGFBeta'ya antikorlar.
ME00832B (me) * 2007-03-22 2012-03-20 Ucb Biopharma Sprl Vezivni proteini uključujući antitjela, derivate antitjela i fragmente antitjela, koji specifično vezuju cd154 i njihova upotreba
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
TW201006485A (en) 2008-06-03 2010-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JO3096B1 (ar) * 2008-11-07 2017-03-15 Imclone Llc الأجسام المضادة لمستقبل ii مضاد tgfb
WO2011102483A1 (ja) * 2010-02-19 2011-08-25 独立行政法人理化学研究所 ヒトTGF-βのLAPに結合する抗体
AR081556A1 (es) 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
MX341578B (es) * 2011-02-08 2016-08-25 Abbvie Inc Tratamiento de la osteoartritis y del dolor.
CN103732623B (zh) * 2011-06-03 2017-09-29 佐马技术有限公司 对TGF‑β具有特异性的抗体
WO2013068902A1 (en) * 2011-11-08 2013-05-16 Pfizer Inc. Methods of treating inflammatory disorders using anti-m-csf antibodies
DK2780368T3 (en) 2011-11-14 2018-02-05 Regeneron Pharma COMPOSITIONS AND PROCEDURES FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH BY SPECIFIC ANTAGONIZATION OF GDF8 AND / OR ACTIVIN A
US9518112B2 (en) * 2012-03-08 2016-12-13 Ludwig Institute For Cancer Research Ltd TGF-β1 specific antibodies and methods and uses thereof
RS61778B1 (sr) * 2013-05-06 2021-06-30 Scholar Rock Inc Kompozicije i postupci za modulaciju faktora rasta
EP3139957A4 (en) * 2014-05-06 2018-04-25 Scholar Rock, Inc. Compositions and methods for growth factor modulation
WO2016115345A1 (en) * 2015-01-14 2016-07-21 The Brigham And Women's Hospital, Treatment of cancer with anti-lap monoclonal antibodies
CA3055555A1 (en) 2016-03-11 2017-09-14 Scholar Rock, Inc. Tgf.beta.1-binding immunoglobulins and use thereof
BR112019013908A2 (pt) * 2017-01-06 2020-02-04 Scholar Rock, Inc. inibidores de tgfss1 isoforma-específicos, contexto-permissivos, e seus usos

Similar Documents

Publication Publication Date Title
JP2020503362A5 (https=)
JP7835788B2 (ja) シトルリン化されたヒストン2a及び/又は4に結合する抗体
KR101676269B1 (ko) 인터루킨-13 결합 단백질
JP6100463B2 (ja) TNFαを阻害する安定かつ可溶性の抗体
JP5164829B2 (ja) 新規な抗plgf抗体
JP2011504501A5 (https=)
JP2018108081A5 (https=)
CN106103479B (zh) 识别其它ccr3-结合趋化因子的抗嗜酸粒细胞趋化因子-2抗体
JP2019505527A5 (https=)
JP2016519650A5 (https=)
JP2008518936A5 (https=)
JP2010527356A5 (https=)
JP2017537084A5 (https=)
JP2018093875A5 (https=)
JP2011518886A5 (https=)
JP2017113019A5 (https=)
JP2017535285A5 (https=)
JP2011518857A5 (https=)
JP2015518857A5 (https=)
JP6383665B2 (ja) IL‐1β中和ヒトモノクローナル抗体
JPWO2020059847A5 (https=)
CN116059350A (zh) 使用抗-il-17a/f抗体的治疗方法
JP2016006052A5 (https=)
JP2023530046A5 (https=)
JP2015515490A5 (https=)